Label expansion strengthens Roche’s portfolio of companion diagnostics
Roche has announced CE label expansion of the VENTANA PD-L1 (SP263) Assay in non-small cell lung cancer (NSCLC) as a companion diagnostic for Tecentriq (atezolizumab). This advances the company’s commitment to...